Top

Published in:

Open Access 01-04-2020 | Crohn's Disease | Review

Perspective on skeletal health in inflammatory bowel disease

Authors: A. A. van Bodegraven, N. Bravenboer

Published in: Osteoporosis International | Issue 4/2020

Abstract

Osteopenia and osteoporosis are common features in inflammatory bowel disease (IBD), comprising both Crohn’s disease and ulcerative colitis. Moreover, Crohn’s disease is associated with increased fracture risk. The etiology of bone loss in IBD is multifactorial. It includes insufficient intake or absorption of calcium, vitamin D, and potassium; smoking; a low peak bone mass; a low body mass index; and decreased physical activity. In several studies, it has been shown that elevated concentrations of systemic and local pro-inflammatory cytokines, including tumor necrosis factor alpha (TNF-α), interferon-γ (IFNγ), interleukin (IL)-1β, IL-4, IL-5, IL-6, IL-13, and IL-17, present in IBD patients are potentially detrimental for bone metabolism and may be responsible for bone loss and increased fracture risk. This perspective aims to review the current literature on the role of inflammatory factors in the pathophysiology of skeletal problems in IBD and to suggest potential treatment to improve bone health, based on a combination of evidence and clinical and pathophysiological reasoning.

Ananthakrishnan AN (2015) Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 12:205–217CrossRefPubMed

van den Heuvel TRA, Jeuring SFG, Zeegers MP, van Dongen D, Wolters A, Masclee AAM, Hameeteman WH, Romberg-Camps MJL, Oostenbrug LE, Pierik MJ, Jonkers DM (2017) A 20-year temporal change analysis in incidence, presenting phenotype and mortality, in the Dutch IBDSL cohort-can diagnostic factors explain the increase in IBD incidence? J Crohns Colitis 11:1169–1179CrossRefPubMed

Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink-van de Kruijs M, Cilissen M, Engels LG, van Deursen C, Hameeteman WH, Wolters FL, Russel MG, Stockbrügger RW (2009) Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 104:371–383CrossRefPubMed

Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN (2000) The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 133:795–799CrossRefPubMed

Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 156:1–10CrossRefPubMed

van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK (2003) Inflammatory bowel disease and the risk of fracture. Gastroenterology 125:1591–1597CrossRefPubMed

Card T, West J, Hubbard R, Logan RF (2004) Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 53:251–255CrossRefPubMedPubMedCentral

Kappelman MD, Galanko JA, Porter CQ, Sandler RS (2011) Risk of diagnosed fractures in children with inflammatory bowel diseases. Inflamm Bowel Dis 17:1125–1130CrossRefPubMed

Tsai MS, Lin CL, Tu YK, Lee PH, Kao CH (2015) Risks and predictors of osteoporosis in patients with inflammatory bowel diseases in an Asian population: a nationwide population-based cohort study. Int J Clin Pract 69:235–241CrossRefPubMed

10.

Szafors P, Che H, Barnetche T, Morel J, Gaujoux-Viala C, Combe B, Lukas C (2018) Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int

11.

Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A (2018) Risk of fractures in inflammatory bowel diseases: a systematic review and meta-analysis. J Clin Gastroenterol

12.

Ferrari S, Bianchi ML, Eisman JA, Foldes AJ, Adami S, Wahl DA, Stepan JJ, de Vernejoul MC, Kaufman JM, Pathophysiology IOFCoSAWGoO (2012) Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 23:2735–2748

13.

Schulte C, Dignass AU, Mann K, Goebell H (1998) Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 4:268–275CrossRefPubMed

14.

Ott C, Scholmerich J (2013) Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 10:585–595CrossRefPubMed

15.

Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, Strid H, Ardizzone S, Veereman-Wauters G, Chevaux JB, Allez M, Danese S, Sturm A, Scientific Committee of the European Crohn’s and Colitis Organization (2011) Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease J Crohns Colitis 5:477–483

16.

Vazquez MA, Lopez E, Montoya MJ, Giner M, Perez-Temprano R, Perez-Cano R (2012) Vertebral fractures in patients with inflammatory bowel disease compared with a healthy population: a prospective case-control study. BMC Gastroenterol 12:47CrossRefPubMedPubMedCentral

17.

Li C, Huang Q, Yang R, Dai Y, Zeng Y, Tao L, Li X, Zeng J, Wang Q (2019) Gut microbiota composition and bone mineral loss-epidemiologic evidence from individuals in Wuhan, China. Osteoporos Int

18.

Chetcuti Zammit S, Ellul P, Girardin G, Valpiani D, Nielsen KR, Olsen J, Goldis A, Lazar D, Shonová O, Nováková M, Sebastian S, Whitehead E, Carmona A, Martinez-Cadilla J, Dahlerup JF, Kievit ALH, Thorsgaard N, Katsanos KH, Christodoulou DK, Magro F, Salupere R, Pedersen N, Kjeldsen J, Carlsen K, Ioannis K, Bergemalm D, Halfvarson J, Duricova D, Bortlik M, Collin P, Oksanen P, Kiudelis G, Kupcinskas L, Kudsk K, Andersen V, O, Morain C, Bailey Y, Doron S, Shmuel O, Almer S, Arebi N, Misra R, Čuković-Čavka S, Brinar M, Munkholm P, Vegh Z, Burisch J (2018) Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. Eur J Gastroenterol Hepatol 30:1297–1303

19.

Briot K, Roux C (2015) Inflammation, bone loss and fracture risk in spondyloarthritis. RMD Open 1:e000052

20.

Oostlander AE, Everts V, Schoenmaker T, Bravenboer N, van Vliet SJ, van Bodegraven AA, Lips P, de Vries TJ (2012) T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for Crohn’s disease-associated bone loss. J Cell Biochem 113:260–268CrossRefPubMed

21.

Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 94:174–181CrossRefPubMedPubMedCentral

22.

Neurath MF, Finotto S (2011) IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22:83–89CrossRefPubMed

23.

Tilg H, Moschen AR, Kaser A, Pines A, Dotan I (2008) Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 57:684–694CrossRefPubMed

24.

Agrawal M, Arora S, Li J, Rahmani R, Sun L, Steinlauf AF, Mechanick JI, Zaidi M (2011) Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep 9:251–257CrossRefPubMed

25.

Nemetz A, Toth M, Garcia-Gonzalez MA, Zagoni T, Feher J, Pena AS, Tulassay Z (2001) Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut 49:644–649CrossRefPubMedPubMedCentral

26.

Tucci M, Stucci S, Savonarola A, Ciavarella S, Cafforio P, Dammacco F, Silvestris F (2013) Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation. Br J Haematol 161:821–831CrossRefPubMed

27.

Sprangers S, Schoenmaker T, Cao Y, Everts V, de Vries TJ (2016) Different blood-borne human osteoclast precursors respond in distinct ways to IL-17A. J Cell Physiol 231:1249–1260CrossRefPubMed

28.

Ganesan R, Rasool M (2017) Interleukin 17 regulates SHP-2 and IL-17RA/STAT-3 dependent Cyr61, IL-23 and GM-CSF expression and RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis. Mol Immunol 91:134–144CrossRefPubMed

29.

Kitaura H, Nagata N, Fujimura Y, Hotokezaka H, Yoshida N, Nakayama K (2002) Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: apoptosis mediated by Fas/Fas ligand interaction. J Immunol 169:4732–4738CrossRefPubMed

30.

Yoshimatsu M, Kitaura H, Fujimura Y, Eguchi T, Kohara H, Morita Y, Yoshida N (2009) IL-12 inhibits TNF-alpha induced osteoclastogenesis via a T cell-independent mechanism in vivo. Bone 45:1010–1016CrossRefPubMed

31.

Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, Kotake S (2007) IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9:R96CrossRefPubMedPubMedCentral

32.

Chen L, Wei XQ, Evans B, Jiang W, Aeschlimann D (2008) IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol 38:2845–2854CrossRefPubMed

33.

Kang YK, Zhang MC (2014) IL-23 promotes osteoclastogenesis in osteoblast-osteoclast co-culture system. Genet Mol Res 13:4673–4679CrossRefPubMed

34.

Kotake S, Nanke Y, Mogi M, Kawamoto M, Furuya T, Yago T, Kobashigawa T, Togari A, Kamatani N (2005) IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol 35:3353–3363CrossRefPubMed

35.

Mirosavljevic D, Quinn JM, Elliott J, Horwood NJ, Martin TJ, Gillespie MT (2003) T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. J Bone Miner Res 18:984–993CrossRefPubMed

36.

Stein NC, Kreutzmann C, Zimmermann SP, Niebergall U, Hellmeyer L, Goettsch C, Schoppet M, Hofbauer LC (2008) Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. J Bone Miner Res 23:750–758CrossRefPubMed

37.

Palmqvist P, Lundberg P, Persson E, Johansson A, Lundgren I, Lie A, Conaway HH, Lerner UH (2006) Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem 281:2414–2429CrossRefPubMed

38.

Frost A, Jonsson KB, Brandstrom H, Ljunghall S, Nilsson O, Ljunggren O (2001) Interleukin (IL)-13 and IL-4 inhibit proliferation and stimulate IL-6 formation in human osteoblasts: evidence for involvement of receptor subunits IL-13R, IL-13Ralpha, and IL-4Ralpha. Bone 28:268–274CrossRefPubMed

39.

Silfversward CJ, Frost A, Brandstrom H, Nilsson O, Ljunggren O (2004) Interleukin-4 and interleukin-13 potentiate interleukin-1 induced secretion of interleukin-6 in human osteoblast-like cells. J Orthop Res 22:1058–1062CrossRefPubMed

40.

Souza PP, Brechter AB, Reis RI, Costa CA, Lundberg P, Lerner UH (2013) IL-4 and IL-13 inhibit IL-1beta and TNF-alpha induced kinin B1 and B2 receptors through a STAT6-dependent mechanism. Br J Pharmacol 169:400–412CrossRefPubMedPubMedCentral

41.

Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA (2002) Effect of Crohn’s disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res 17:695–702CrossRefPubMed

42.

Varghese S, Wyzga N, Griffiths AM, Sylvester FA (2002) Effects of serum from children with newly diagnosed Crohn disease on primary cultures of rat osteoblasts. J Pediatr Gastroenterol Nutr 35:641–648CrossRefPubMed

43.

Oostlander AB, N; Lems, WF; Klein-Nulend, J; Schulten, EA; van Bodegraven, AA; Lips, P. (2008) Effect of proinflammatory cytokines and serum of Crohn’s disease patients on primary human osteoblast proliferation. CALCIFIED TISSUE INTERNATIONAL, pp S113-S113

44.

Karsenty G, Gershon MD (2011) The importance of the gastrointestinal tract in the control of bone mass accrual. Gastroenterology 141:439–442CrossRefPubMed

45.

Yadav VK, Balaji S, Suresh PS, Liu XS, Lu X, Li Z, Guo XE, Mann JJ, Balapure AK, Gershon MD, Medhamurthy R, Vidal M, Karsenty G, Ducy P (2010) Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 16:308–312CrossRefPubMedPubMedCentral

46.

Lavoie B, Roberts JA, Haag MM, Spohn SN, Margolis KG, Sharkey KA, Lian JB, Mawe GM (2019) Gut-derived serotonin contributes to bone deficits in colitis. Pharmacol Res 140:75–84CrossRefPubMed

47.

Nielsen OH, Rejnmark L, Moss AC (2018) Role of vitamin D in the natural history of inflammatory bowel disease. J Crohns Colitis 12:742–752CrossRefPubMed

48.

Kiela PR, Ghishan FK (2016) Physiology of intestinal absorption and secretion. Best Pract Res Clin Gastroenterol 30:145–159CrossRefPubMedPubMedCentral

49.

Krawitt EL, Beeken WL, Janney CD (1976) Calcium absorption in Crohn’s disease. Gastroenterology 71:251–254CrossRefPubMed

50.

Ghishan FK, Kiela PR (2017) Vitamins and minerals in inflammatory bowel disease. Gastroenterol Clin N Am 46:797–808CrossRef

51.

Sitrin MD, Pollack KL, Bolt MJ (1985) Intestinal absorption of 1,25-dihydroxyvitamin D3 in the rat. Am J Phys 248:G718–G725

52.

Kuchuk NO, van Schoor NM, Pluijm SM, Chines A, Lips P (2009) Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res 24:693–701CrossRefPubMed

53.

Larmonier CB, McFadden RM, Hill FM, Schreiner R, Ramalingam R, Besselsen DG, Ghishan FK, Kiela PR (2013) High vitamin D3 diet administered during active colitis negatively affects bone metabolism in an adoptive T cell transfer model. Am J Physiol Gastrointest Liver Physiol 305:G35–G46CrossRefPubMedPubMedCentral

54.

Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ (2000) Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 54:514–521CrossRefPubMed

55.

Scaldaferri F, Pizzoferrato M, Lopetuso LR et al (2017) Nutrition and IBD: malnutrition and/or sarcopenia? A practical guide. Gastroenterol Res Pract 2017:8646495CrossRefPubMedPubMedCentral

56.

Bryant RV, Ooi S, Schultz CG, Goess C, Grafton R, Hughes J, Lim A, Bartholomeusz FD, Andrews JM (2015) Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther 41:895–906CrossRefPubMed

57.

Laakso S, Valta H, Verkasalo M, Toiviainen-Salo S, Makitie O (2014) Compromised peak bone mass in patients with inflammatory bowel disease--a prospective study. J Pediatr 164:1436–1443 e1431

58.

Suibhne TN, Cox G, Healy M, O’Morain C, O’Sullivan M (2012) Vitamin D deficiency in Crohn’s disease: prevalence, risk factors and supplement use in an outpatient setting. J Crohns Colitis 6:182–188

59.

Miller HL, Farraye FA, Coukos J, Howard LA, Holick MF, Stucchi AF, Becker JM (2013) Vitamin D deficiency and insufficiency are common in ulcerative colitis patients after ileal pouch-anal anastomosis. Inflamm Bowel Dis 19:E25–E26CrossRefPubMed

60.

Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A (1995) Prevention of bone mineral loss in patients with Crohn’s disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 7:609–614PubMed

61.

Melek J, Sakuraba A (2014) Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review. Clin Gastroenterol Hepatol 12:32–44 e35

62.

Robinson RJ, Krzywicki T, Almond L, al-Azzawi F, Abrams K, Iqbal SJ, Mayberry JF (1998) Effect of a low-impact exercise program on bone mineral density in Crohn’s disease: a randomized controlled trial. Gastroenterology 115:36–41

63.

Schulte C, Dignass AU, Mann K, Goebell H (1999) Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol 34:696–702CrossRefPubMed

64.

Targownik LE, Bernstein CN, Leslie WD (2014) Risk factors and management of osteoporosis in inflammatory bowel disease. Curr Opin Gastroenterol 30:168–174CrossRefPubMed

65.

Robinson RJ, Iqbal SJ, Al-Azzawi F, Abrams K, Mayberry JF (1998) Sex hormone status and bone metabolism in men with Crohn’s disease. Aliment Pharmacol Ther 12:21–25CrossRefPubMed

66.

Tew GA, Jones K, Mikocka-Walus A (2016) Physical activity habits, limitations, and predictors in people with inflammatory bowel disease: a large cross-sectional online survey. Inflamm Bowel Dis 22:2933–2942CrossRefPubMed

67.

Buckley L, Guyatt G, Fink HA et al (2017) 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69:1521–1537CrossRefPubMed

68.

Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z (2006) Infliximab therapy improves the bone metabolism in fistulizing Crohn’s disease. Dig Dis 24:201–206CrossRefPubMed

69.

Veerappan SG, O’Morain CA, Daly JS, Ryan BM (2011) Review article: the effects of antitumour necrosis factor-alpha on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 33:1261–1272

70.

Sugimoto K, Ikeya K, Iida T et al (2016) An increased serum N-terminal telopeptide of type I collagen, a biochemical marker of increased bone resorption, is associated with infliximab therapy in patients with Crohn’s disease. Dig Dis Sci 61:99–106CrossRefPubMed

71.

Krajcovicova A, Hlavaty T, Killinger Z et al (2014) Combination therapy with an immunomodulator and anti-TNFalpha agent improves bone mineral density in IBD patients. J Crohns Colitis 8:1693–1701CrossRefPubMed

72.

Leichtmann GA, Bengoa JM, Bolt MJ, Sitrin MD (1991) Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn’s disease and intestinal resection. Am J Clin Nutr 54:548–552CrossRefPubMed

73.

Bakker SF, Dik VK, Witte BI, Lips P, Roos JC, Van Bodegraven AA (2013) Increase in bone mineral density in strictly treated Crohn’s disease patients with concomitant calcium and vitamin D supplementation. J Crohns Colitis 7:377–384CrossRefPubMed

74.

Raftery T, O’Morain CA, O’Sullivan M (2012) Vitamin D: new roles and therapeutic potential in inflammatory bowel disease. Curr Drug Metab 13:1294–1302

75.

Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F (1996) A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 10:777–786CrossRefPubMed

76.

Benchimol EI, Ward LM, Gallagher JC, Rauch F, Barrowman N, Warren J, Beedle S, Mack DR (2007) Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 45:538–545CrossRefPubMed

77.

Hu Y, Chen X, Chen X, Zhang S, Jiang T, Chang J, Gao Y (2017) Bone loss prevention of bisphosphonates in patients with inflammatory bowel disease: a systematic review and meta-analysis. Can J Gastroenterol Hepatol 2017:2736547CrossRefPubMedPubMedCentral

78.

van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude C, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand R, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P, Dutch Initiative on Crohn and Colitis (ICC) (2014) Treatment of bone loss in osteopenic patients with Crohn’s disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation. Gut 63:1424–1430CrossRefPubMed

79.

Ferrari-Lacraz S, Ferrari S (2011) Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int 22:435–446CrossRefPubMed

80.

Dubrovsky AM, Lim MJ, Lane NE (2018) Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton. Calcif Tissue Int 102:607–618CrossRefPubMed

81.

Kinoshita H, Miyakoshi N, Kashiwagura T, Kasukawa Y, Sugimura Y, Shimada Y (2017) Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis. Mod Rheumatol 27:582–586CrossRefPubMed

82.

McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723–1732CrossRefPubMedPubMedCentral

83.

Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627–1633CrossRefPubMedPubMedCentral

Title: Perspective on skeletal health in inflammatory bowel disease
Authors: A. A. van Bodegraven
N. Bravenboer
Publication date: 01-04-2020
Publisher: Springer London
Keywords: Crohn's Disease
Chronic Inflammatory Bowel Disease
Osteoporosis
Osteoporosis
Cytokines
Published in: Osteoporosis International / Issue 4/2020
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-019-05234-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Perspective on skeletal health in inflammatory bowel disease

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study

Incidence of distal radius fracture in a general population in southern Sweden in 2016 compared with 2001

Education intervention for older adults with osteoporosis: a systematic review

Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?

Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women

Bone strength of the proximal femur in healthy subjects with ossification of the posterior longitudinal ligament